What is seqWell?
SeqWell, headquartered in Beverly, Massachusetts, is a global player in the development of advanced NGS library construction technologies. Its proprietary plexWell platform is engineered to streamline the sample preparation process for NGS, offering improvements in throughput, quality, and utility across various NGS platforms. The company's mission is to redefine industry standards by providing enhanced library preparation solutions and simplified application workflows, catering to the increasing demands for efficient and scalable genomic analysis.
How much funding has seqWell raised?
seqWell has raised a total of $17.4M across 4 funding rounds:
Private Equity
$1.3M
Series B
$9M
Debt
$150K
Series C
$7M
Private Equity (2016): $1.3M, investors not publicly disclosed
Series B (2020): $9M led by Research and BroadOak Fund
Debt (2020): $150K supported by PPP
Series C (2022): $7M featuring Codexis, Research, and BroadOak Capital Partners
Key Investors in seqWell
Codexis
Codexis is a leading enzyme engineering company that leverages its proprietary CodeEvolver platform to develop high-performance enzymes for various applications, including therapeutics manufacturing and molecular diagnostics. Their involvement suggests a strategic interest in seqWell's technology for potential integration or advancement in biopharmaceutical processes.
Research
Research Corp is a company operating in the Research & Development industry, focusing on innovation and scientific advancement. Their participation indicates a commitment to supporting novel technologies and potentially contributing to seqWell's ongoing research and development efforts.
BroadOak Capital Partners
BroadOak Capital Partners is a financial institution specializing in direct investment and banking services for life sciences and biopharma services companies. Their investment in seqWell highlights their focus on growth capital for companies within the life sciences tools and diagnostics sectors.
What's next for seqWell?
The recent major strategic investment positions seqWell for accelerated expansion and further technological development. With a clear focus on scaling its operations and enhancing its market presence, the company is poised to capitalize on the growing demand for high-throughput genomic sequencing solutions. Future endeavors will likely involve expanding its product portfolio, forging new strategic partnerships, and potentially exploring new market segments within the life sciences and diagnostics industries. The sustained backing from investors suggests a strong belief in seqWell's ability to innovate and lead in the competitive NGS technology landscape.
See full seqWell company page
